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ABSTRACT 
 
Impact of Collateral Enlargement on Smooth Muscle Phenotype 
 
Alexander Bynum 
 
Peripheral Artery Disease is a very serious disease characterized by an arterial occlusion 
due to atherosclerotic plaques. In response to an arterial occlusion, arteriogenesis occurs, 
causing smooth muscle cells to transition from a contractile to synthetic state. Also 
following an arterial occlusion, functional impairment was seen in the collateral circuit. 
An immunofluorescence protocol was developed in order to assess the impact of 
collateral enlargement (arteriogenesis) on smooth muscle phenotype at various time 
points. Smooth muscle α-actin was used to mark all smooth muscle cells, Ki-67 was used 
to label proliferating smooth muscle cells, and a fluorescent nuclear stain was used to 
quantify the number of cells present. Samples of the profunda femoris and gracilis were 
dissected from each mouse hind limb (one ligated, one sham) at three different time 
points: 3 days, 7 days, and 14 days after a femoral artery ligation surgery. Smooth muscle 
cell phenotype and luminal cross-sectional area were assessed in the profunda femoris 
and the midzone of the gracilis collaterals. Smooth muscle cells were proliferating at 3 
and 7 days following the occlusion in the gracilis collaterals and significant collateral 
vessel growth was observed over the two week period. No proliferation was observed in 
the profunda femoris and although there was an increasing trend in vessel size over the 
two week period, the averages were not significantly different. The phenotypic transition 
of the smooth muscle cells was not the cause of vascular impairment in the collateral 
circuit. This shows that further research is needed to characterize impairment in the 
collateral circuit. 
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Introduction 
Normal Vascular Anatomy and Function 
The Circulatory System 
The circulatory system supplies the body’s tissue with oxygen and nutrients while 
simultaneously removing carbon dioxide and other waste products for excretion by the 
lungs and kidneys. This exchange of gases, water, and solutes between the vascular and 
interstitial fluid compartments occurs mainly in the capillaries, in which the vessel wall 
consists of a single endothelial cell and associated perivascular cells. While distributing 
essential substances to the tissues and removing the by-products of metabolism, the 
circulatory system also maintains homeostasis through evaporative cooling, delivering 
endocrine products, and adjusting oxygen and nutrient supply for different physiological 
states [1].  
The heart that supplies this circulatory system is comprised of two pumps, or ventricles, 
in series. The right ventricle works to propel blood through the lungs for exchange of 
oxygen and carbon dioxide; this is referred to as the pulmonary circulation. The left 
ventricle works to propel blood to all other tissues of the body, the systemic circulation. 
From the heart, the blood is pumped into the aorta, the largest of the arteries. After the 
blood moves from the aorta into the large network of arteries, it flows into small arteries 
and arterioles, which are the resistance vessels of the circulation. The diameter, or 
vascular tone, of these vessels, coupled with the output of the left ventricle, determine the 
distribution of the circulation. Once blood leaves these arterioles, it moves into the 
capillaries for nutrient and waste exchange. Once blood leaves the capillaries it enters the 
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network of venules followed by the larger veins, and finally the largest vein, the vena 
cavae. From the vena cavae, the blood flows back into the heart to be pumped into the 
lungs. This unidirectional flow through the heart is achieved by the appropriate 
arrangement of valves. Although the cardiac output is intermittent, continuous flow to the 
periphery occurs by distension of the aorta and its branches during ventricular contraction 
(systole) and elastic recoil of the walls of the large arteries with forward propulsion of the 
blood during ventricular relaxation (diastole). After the blood flows from the heart into 
the aorta, a predominantly elastic structure, the peripheral arteries become more muscular 
until the muscular layer predominates at the arterioles [1]. 
In a normal intact circulation, the total volume of blood is constant, and an increase in the 
volume of blood in one area must be accompanied by a decrease in another. This 
distribution of the circulating blood to the various regions of the body is determined by 
the vascular tone of the resistance vessels (small arteries and arterioles) in these regions. 
The circulatory system is composed of these various conduits arranged in series and in 
parallel as displayed in Figure 1 [1]. 
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Between the aorta and the capillaries, the number of vessels increases up to 3 billion-fold, 
and the total cross-sectional area increases about 500-fold. The volume of blood in the 
systemic vascular system is greatest in the veins and venules, which contain about 67% 
of the body’s blood during rest. Only 5% of the total blood volume is located in the 
capillaries and only 11% of the blood is contained in the aorta, arteries, and arterioles 
collectively. In contrast, blood volume in the pulmonary vascular bed is about equally 
divided among the arterial, capillary, and venous vessels [1].  
 
 
Figure 1 Schematic diagram of the parallel and series arrangement of the vessels 
composing the circulatory system[1]. 
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Smooth Muscle Cell Function in the Arterial Network 
Smooth muscle cells (SMCs), are inherently important to the circulation because of their 
role in the regulation of vascular tone (i.e. blood pressure and blood flow control). 
Although SMCs are located in all vessel walls, vascular tone and the distribution of blood 
are determined by the contractile state of SMCs within the arteriole and small/muscular 
artery wall. 
 While smooth muscle cells are different than cardiac or skeletal muscle cells, they do 
have many individual similarities to striated muscle. For instance, smooth muscle cells 
contain many of the same types of organelles and contractile proteins that can be found in 
skeletal muscle. Unlike skeletal muscle, embryonic smooth muscle cells do not fuse, and 
each differentiated cell has a single, centrally located nucleus. SMCs are typically 40 to 
600 µm long and are 2 to 10µm in diameter in the region of the nucleus, with most cells 
exhibiting a spindle shape [4].  
There are various types of smooth muscle cells that can be categorized based on their 
method of stimulation, their level of connection with other SMCs, or their activity 
patterns. Vascular smooth muscle cells (VSMCs), in particular, are considered multiunit 
SMCs because most are not electrically coupled. This means that the stimulation of one 
cell does not necessarily result in activation of adjacent cells. This is in contrast to single 
unit SMCs, in which all cells are electrically coupled, resulting in consecutive stimulation 
of adjacent cells (e.g. SMCs in the gut during peristalsis). VSMCs can also be classified 
as tonic smooth muscle cells because they are, at times, continuously active [4]. During 
tonic contraction, myoplasmic Ca
++
 and cross-bridge phosphorylation decline after an 
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initial spike followed by a slow increase in force, eventually tapering off at a high level. 
Referred to as the “latch state,” this sustained force is maintained with only 20% to 30% 
of the cross-bridges phosphorylated, and thus ATP utilization is reduced. Smooth muscle 
cells use 300-fold less ATP than would be required by skeletal muscle to generate the 
same force with fatigue only occurring if the cells are deprived of oxygen [4].  
The contractile state of vascular smooth muscle cells within the arteriole and 
small/muscular artery wall is regulated by intercellular calcium concentration [5]. A rise 
in intercellular calcium is usually due to an action potential or the presence of a 
hormone/agonist. This rise in intracellular [Ca
2+
] results in the binding of [Ca
2+
]  ions to 
calmodulin, creating a complex that activates myosin light-chain kinase (MLCK), which 
phosphorylates the regulatory light chain of myosin [4]. This phosphorylation, along with 
an ATP molecule to energize each myosin cross-bridge, is critical for the interaction of 
smooth muscle myosin and actin in the development of force [4]. When myoplasmic 
[Ca
2+
] falls, MLCK becomes inactive, and the cross-bridges are dephosphorylated (i.e. 
cross-bridge cycling stops) [4]. This myosin cross-bridge cycling is similar to that of 
striated muscle in that it involves a ratcheting action of the myosin head that pulls the thin 
filament toward the center of the thick filament, causing a generation of force. However, 
the kinetics of cross-bridge cycling is slower for smooth muscle cells, and unlike striated 
muscle, cannot occur if the regulatory light chain of myosin is not phosphorylated [4]. 
Also, in contrast to striated muscle, the sensitivity of contraction to [Ca
2+
] is variable in 
smooth muscle, in that different agonists can increase the force of contraction at 
submaximal levels of intracellular [Ca
2+
] [4]. 
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 A variety of drugs and hormones relax smooth muscle by increasing the cellular 
concentrations of cyclic nucleotides, such as cGMP. Soluble guanylyl cyclase (sGC), a 
receptor for nitric oxide (NO), produces cGMP. Increases in cGMP promote the 
activation of protein kinase G, which inactivates myosin light chain kinase, causing the 
actin-myosin cross-bridge cycling to cease [4]. So, by increasing cGMP, NO, produced 
by nerves and vascular endothelial cells, relaxes smooth muscle [4].  A reduction in 
intracellular [Ca
2+
], associated with the relaxation of smooth muscle, is usually via 
stimulation of [Ca
2+
] pumps in the sarcolemma, the sarcoplasmic reticulum (SR) or both 
[4].  Acetylcholine released from parasympathetic fibers also causes vasodilation in some 
vascular beds as a result of the production of NO by vascular endothelial cells [4]. 
Vasoconstrictors and vasodilators use two methods, often simultaneously, to stimulate 
contraction and dilation, respectively. They can adjust sensitivity to [Ca
2+
] or change the 
levels of intracellular [Ca
2+
] in VSMCs. In contrast, an elevation in endothelial [Ca
2+
] 
induces relaxation of the adjacent VSMCs. Therefore, fine tuning of [Ca
2+
] in both cell 
types is imperative for precise regulation of organ and tissue perfusion [5]. 
The contractile activity of SMCs are systemically controlled by the autonomic nervous 
system, specifically, vascular smooth muscle cells are primarily innervated by 
sympathetic fibers [4]. Sympathetic fibers, using norepinephrine (NE) as a 
neurotransmitter, stimulate α1-adrenergic receptors on VSMCs. Binding of NE causes the 
G protein dependent activation of phospholipase C (PLC), which results in the production 
of inositol 1,4,5-triphosphate (IP3). Elevated levels of IP3 activates the IP3-gated [Ca
2+
] 
channel in the SR, which results in an increase of myoplasmic [Ca
2+
] and leads to 
vasoconstriction [4].   Although VSMCs are primarily controlled by adrenergic 
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stimulation, their contractility is still susceptible to muscarinic stimulation via 
acetylcholine, as mentioned above [4]. The tone of the SMCs, as discussed above, is 
subject to local influence from circulating hormones and neighboring endothelial and 
skeletal muscle cells via diffusable substances such as NO and adenosine [4]. VSMC tone 
can also be stimulated by physical stretch, a phenomenon called the myogenic response. 
VSMCs will contract in response to an increase in transumural pressure stretch and relax 
in response to a decrease in transmural pressure [1]. An initial flow increment produced 
by an abrupt increase in perfusion pressure that passively distends the blood vessels 
would be followed by a return of flow to the previous control by contraction of the 
VSMCs in the resistance vessels [1]. 
Smooth muscle function can be controlled systemically or locally, via the nervous 
system, endocrine system, or physical stretch. These alterations in smooth muscle 
contractility and vascular tone facilitate adjustments in blood flow in order meet the 
oxygen demands of various parts of the body on an acute basis [4]. 
 
Vasculature Adaptations 
Acute changes in blood flow are brought on by vascular responses such as a change in 
smooth muscle contractility and vascular tone. However, if blood flow is consistently 
altered, the vessel will experience chronic changes (i.e. vascular adaptations). Arterial 
occlusion is a common stimulus for chronic changes in blood flow. An arterial occlusion 
induces both angiogenesis, the sprouting of the capillaries, as well as arteriogenesis, the 
growth/remodeling of pre-existent arterioles into conduit arteries [6].  
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Interarterial connections associated with arteriogenesis are called collateral vessels or 
anastomoses [6]. These vessels are present in almost all organs. During arteriogenesis, 
the vessels can enlarge to an astonishing degree and can function under favorable 
conditions as efficient blood conductors preventing or limiting tissue necrosis [6]. 
Physical factors such as fluid shear stress are well established as the initiating events of 
arteriogenesis. Although angiogenesis plays an important role in the adaptation to arterial 
occlusion due to hypoxia in the downstream tissue, arteriogenesis is more efficient at 
restoring blood flow [6]. It has been shown that arteriogenesis can also prevent 
angiogenesis by restoring blood flow to the ischemic tissue and that ischemia is not the 
direct driving force in arteriogenesis [6]. 
 
Angiogenesis 
Although angiogenesis is a normal vascular adaptation, it also occurs in many diseases, 
including cancer, diabetic retinopathy, and atherosclerosis. Anti-angiogenic agents have 
entered clinical use for cancer and eye disease and angiogenesis has been  proposed as a 
treatment for of ischemic diseases [7]. 
Angiogenesis occurs through multiple, complementary roles in normal or pathological 
angiogenesis [7]. Pathological angiogenesis often occurs in response to hypoxia which 
causes endothelial cells and parenchymal cells to increase the transcription of hypoxia-
inducible factor-1 (HIF-1), which upregulates vascular endothelial growth factor (VEGF) 
[8]. As a result of an increase in VEGF, proteolytic degradation of the extracellular 
martrix occurs, followed by chemotactic migration and proliferation of endothelial cells, 
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the formation of a lumen, and the functional maturation of the endothelium [8]. The result 
of this sprouting angiogenesis is a newly formed capillary loop in the once hypoxic 
tissue. 
Arteriogenesis 
Arteriogenesis is the process whereby a preexisting arteriole outwardly remodels into a 
conductance artery. An example would be in the case of an occlusion of the femoral 
artery in the mouse hindlimb. Collateral vessels enlarge in the upper leg between 
proximal and distal side branches, relatively close to the site of occlusion (due to the 
large changes in hemodynamics) [3]. In contrast, ischemia induces hypoxia in the lower 
leg and the foot, which causes angiogenesis to occur [3].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Laser Doppler image of collateral blood flow in an anesthetized 
mouse with exposed upper thigh skeletal muscles with chronic occlusion 
(7days) of the left femoral artery [3]. 
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As we can see from Figure 2, the superficial adductor muscles in the murine upper leg 
have a dual arterial blood supply. Different side branches enter the muscle from both 
medial and lateral ends and taper down; the primary arterioles from both side branches 
meet and connect in the middle of the muscle, forming an anastomosis [3]. 
The collateral vessel is associated with three different zones: the stem, mid-zone and 
reentry. The stem is characterized by the feed vessel to the collateral (the profunda 
femoris in Figure 2). The mid-zone is characterized by the middle of the collateral, 
where the greatest degree of arteriogenesis usually occurs post occlusion (the gracilis 
collaterals in Figure 2). Reentry is the area where the collateral supplies blood flow 
downstream of the occluded vessel (where the gracilis collateral meets the saphenous 
artery in Figure 2).  
As a result of an arterial occlusion, the rerouting of blood in the collateral circuit causes 
an increase in shear stress on the vessel wall. These changes in wall stress and shear 
stress are sensed by the endothelium, which up-regulates growth factors and secrete nitric 
oxide (NO) and prostacyclin [3]. Eventually the chronic increased shear stress causes the 
activated endothelium to lose volume control and swell [3]. When this mechanical force 
is transmitted from the deformed cell it will activate transcription factors, such as egr-1, 
which will up-regulate chemokines like MCP-1 and adhesion molecules like intracellular 
adhesion molecule-1 (ICAM-1), which are necessary monocyte docking [3]. Monocytes 
are crucial to facilitating arteriogenesis and suppression of them significantly delaya 
arteriogenesis [3]. 
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The midzone of growing collaterals is surrounded by a perivascular inflammatory 
infiltrate, consisting mainly of monocytes and T-lymphocytes. These cells have migrated 
partially from the arterial lumen. The media of these vessels is thus surrounded from both 
sides by inflammatory cells that secrete growth factors and proteases that are necessary to 
remodel the old media. T-lymphocytes are also necessary to destroy cells in the close 
vicinity of the collateral artery to create the space to be occupied by the greatly expanded 
vessel [3]. 
Remodeling begins after the acute phase of arteriogenesis, which is dominated by the 
inflammatory events (i.e. endothelium activation and extravasation of monocytes and T-
lymphocytes).  The process begins with the upregulation of matrixmetalloproteinases 
(MMPs), a type of protease that digests the extracellular matrix of the vessel wall and 
provides space for new cells and enables SMCs to migrate away from the intima to create 
a new, larger conductance vessel [3]. A new elastic lamina is synthesized by the smooth 
muscle cells  (SMCs), and the rebuilding of the media and the formation of an intima 
begins with the upregulation of the tissue inhibitor of MMPs [3]. The role of SMCs in 
arteriogenesis will be discussed later in more detail, as they are a key component in this 
study. 
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Perpherial Artery Disease and Atherogenesis 
Perpherial Artery Disease (PAD), the most common cause of peripheral arterial occlusion 
in patients, is characterized by fatty deposits in the inner linings of the artery walls. These 
fatty deposits can restrict blood circulation to the periphery, causing the downstream 
tissue to become ischemic, often leading to serious health problems in the individual. 
PAD affects a large segment of the adult population, with an age-adjusted prevalence of 
4% to 15%, affecting more than 5 million adults in the United States and increasing up to 
30% with age and the presence of cardiovascular risk factors. Twenty percent of patients 
with PAD have typical symptoms of intermittent leg-muscle discomfort on exertion, 
ulceration or gangrene. Another third  of patients have atypical exertional leg symptoms 
[9]. 
Age and gender-adjusted risk factors associated with the development of PAD are similar 
to the traditional risk factors for atherosclerosis, which include: cigarette smoking, 
diabetes, hyperlipidemia, hypertension, hyperhomocystinemia and chronic renal 
insufficiency [10]. Smoking and diabetes are the strongest risk factors and are associated 
with more aggressive disease progression [9]. The relative risk of claudication is 3.7 
times the normal risk in current smokers and 3 times in ex-smokers [11]. Also, the 
presence of diabetes increases the risk of PAD by 2- to 4-fold with 5- to 10-times higher 
need for major amputation in diabetics compared to non-diabetics [12]. 
Studies of the natural history of PAD indicate that the risk of ischemic limb events for 
non-diabetic patients is relatively low, with less than 2% requiring major or minor 
amputation. Although intermittent claudication can lead to less exercise, causing obesity, 
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osteoporosis, etc., cardiovascular disease and manifestations of atherosclerosis in other 
vascular beds are the major determinants of prognosis in these patients [9]. There is 
approximately a 2- to 4-fold increase in coronary and cerebrovascular disease in patients 
with PAD, with an annual rate of 5-7% for cardiovascular events (myocardial infarction, 
stroke, or death from cardiovascular causes) [10]. Notably, the risk of cardiovascular 
morbidity and mortality is similar in all patients with PAD, regardless of the presence of 
symptoms [13]. Therefore, managements of the disease are directed not only at 
improving symptoms of claudication and the lower limb ischemia, but more importantly 
at reducing the overall cardiovascular risk [9]. 
Mechanisms Involved in the Development of Atherosclerotic Plaques 
This build up of fatty deposits, or atherosclerosis, is characterized by lipid deposition and 
inflammation in the artery wall. Cholesterol is the major lipid species in artherosclerotic 
lesions and accumulates in both unesterfied and esterfied forms [14]. 
Atherosclerosis is also characterized by plaques consisting of necrotic cores, calcified 
regions, accumulated modified lipids, inflamed smooth muscle and endothelial cells, 
leukocytes, and foam cells. As described, atherosclerosis is a disease that involves 
components of the vascular, metabolic, and immune systems [2]. 
The occurrence of inflammatory cells in atherosclerotic lesions depends on the rate of 
their recruitment and egress and the balance of proliferation, survival, and apoptosis 
within the arterial wall [2]. The following figure diagrams the mechanisms involved in 
the development of atherosclerosis. 
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The endothelial cells above the lesion are polygonal in shape, whereas the normal 
endothelial cells are aligned with the direction of flow [2]. Also, the normal intima is 
usually very thin, and would be almost invisible except at the highest resolutions, but the 
neointima is greatly expanded in the lesion area [2]. In this area, there are vascular 
dendritic cells, macrophages, foam cells, and T lymphocytes [2]. The foam cells surround 
the necrotic core, which is composed of foam cells that have undergone necrosis [2]. The 
normal media is populated by smooth muscle cells that are organized between an internal 
and external elastic laminae. Myeloid cells invade the media in the lesion area, while the 
Figure 3 Immune and inflammatory cells in atherosclerosis[2]. 
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normal adventitia is populated by sparse T cells, B cells, lymphocytes, and dendritic 
cells. In the lesion area, lymphocytes induce an angiogenesis in the vasovasorum that is 
thought to destabilize plaque and precipitate rupture events [2]. 
Diagnosis and Management of PAD 
Atherosclerosis eventually leads to a reduced blood flow distal to the injury, causing 
ischemia in the downstream tissue. Although there are no cures for this disease, there are 
ways to diagnose and manage the symptoms. Initial evaluations include a careful history 
and physical examination with shoes and socks removed to assess for signs of acute or 
chronic peripheral ischemia, with attention to peripheral pulses, hair loss, skin color, and 
trophic skin changes [9]. The abdomen is also examined for evidence of an aortic 
aneurysm and blood pressure is measured in both arms[9]. Also, a stethoscope is used to 
check for sounds of turbulent flow at the neck, and over the clavicles, as well as pulses in 
the abdomen and femoral region [9]. Upon clinical suspicion for PAD, referral to a 
vascular laboratory is the initial step for noninvasive diagnostic assessment of the 
location and severity of the arterial disease. These noninvasive tests can also be repeated 
over time to follow the disease progression and response to medical treatment or 
revascularization[9]. Some of these tests include ankle-brachial pressure measurement or 
noninvasive imaging techniques [9]. 
In attempts to manage PAD, patients will undergo risk factor modification, an exercise 
program, pharmacologic treatment, and endovascular or surgical revascularization. In 
most cases, revascularization is reserved for patients experiencing significant disability. 
Patient-specific managements may include smoking cessation programs, aggressive 
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control of hyperglycemia, and lipid-lowering to reduce the risk of cardiovascular events 
due to atherosclerosis [9]. 
Current treatments for PAD 
Once PAD has been diagnosed, there are various treatments available. The extensiveness 
of the treatment often depends on the progression of the disease in the patient. The most 
efficacious treatment is exercise, which significantly improves walking time and overall 
walking ability in patients with intermittent claudication [10]. Notably, exercise may be 
more effective than antiplatelet therapy in improving maximal walking time and have 
equivalent efficacy to surgery [10]. Furthermore, physical activity both prevents and 
helps treat many established atherosclerotic risk factors, such as elevated blood pressure, 
insulin resistance and glucose intolerance, elevated triglyceride concentrations and low 
high-density lipoproteins [9]. Habitual physical activity also helps to reduce 
inflammation, which is associated with the pathogenesis of atherosclerosis [9]. 
If there is a serious hindrance on a patient's quality of life, or they have a reduced 
exercise capacity, antiplatelet therapy may be suggested. Antiplatelets are a class of drugs 
that decrease platelet aggregation and inhibit thrombus formation. In patients at high risk 
of arterial occlusive disease, antiplatelet therapy with aspirin reduces the risk of 
myocardial infarction, stroke and cardiovascular death by 25% [15]. Although aspirin has 
not been shown to improve claudication, it delays the progression of PAD, reduces the 
need for intervention, and reduces graft failure in patients who have undergone surgery 
[9]. Clopidogrel is another anti-platelet therapy that has been shown to reduce the risk of 
myocardial infarction, stroke or cardiovascular death. Because aspirin is cheaper and 
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easier to obtain, clopidogrel is currently only recommended as an effective alternative for 
those who may be allergic to aspirin or other NSAIDs. There are also many other anti-
platelet therapies available, but these are less beneficial than aspirin in patients with PAD 
because of the associated increased risk of major bleeding in the patient [9]. 
If antiplatelet therapies are not sufficient, there are other pharmacological agents that 
specifically treat claudication. Cilostazol is a proficient treatment for claudication 
because it is a vasodilator with mild anti-platelet properties. Treatment with cilostazol 
significantly increases maximal and pain-free walking distance and may improve the 
quality of life in patients with PAD. Although there are other options to cilostazol, they 
have been shown to be less effective at treating claudication [16]. 
Since there is often an inadequate response to exercise or the previously discussed 
pharmacological therapies, researchers continue to search for new therapies. The use of 
angiogenic growth factors, such as vascular endothelial growth factor (VEGF), 
recombinant fibroblast growth factor 2 (rFGF-2) and hypoxia-inducible factor-1, have 
generated considerable enthusiasm as potential treatments of PAD because of their role in 
the stimulation of new vessel growth [9]. Clinical studies on delivering single growth 
factors intramuscularly were not successful. Recent applications have effectively 
integrated the use of gene transfer strategies of angiogenic proteins, but these applications 
still prove ineffective [17].  More studies and trials need to be conducted to assess the 
overall efficacy and safety of these growth factors [17]. 
Although exercise and pharmalogical treatments have proven to be somewhat effective at 
combating the symptoms and slowing the progression of PAD, some patients may have 
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more severe cases in which these methods prove ineffective [9]. With these patients, 
endovascular treatments are often suggested. Endovascular techniques to treat PAD 
include percutaneous transluminal angioplasty (PTA) with balloon dilation, endografts, 
atherectomy, cutting balloons, drug-coated balloon angioplasty, cryoplasty, percutanoues 
thrombectomy and brachytherapy [9]. From all of the therapies listed above, PTA is the 
recommended initial endovascular treatment for PAD [10]. 
Endovascular stenting is also another form of treatment for PAD because it avoids the 
problems of early elastic recoil, residual stenosis and flow-limiting dissection after 
balloon angioplasty and thus can be used to treat long and calcified lesions. Although 
stent designs continue to improve over the years, more data is required to improve 
patency while reducing the chance of fracture [18].  
Initial attempts have been made using newer technologies, such as drug-eluting stents and 
balloons that have proved beneficial as percutaneous coronary intervention (PCI) 
techniques. However, this technology has not yet been successful when used in the 
peripheral arteries [19]. Aside from the previously described endovascular therapies, 
there are still many emerging endovascular technologies. While these methods are 
currently being investigated, their role in the treatment of PAD still remains controversial 
[9]. 
As the population ages, it is anticipated that the prevalence of PAD will increase[9]. 
Although there has been a rapid evolution of technology for treatments, there are still 
vital improvements that need to be made in the future. All non-interventional techniques  
either treat symptoms or slow the disease and interventional techniques are often 
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dangerous and complicated. While these treatments can slow the dangers associated with 
the disease, there is still a need to better understand the progression of atherosclerosis. By 
studying the development of atherosclerosis and its side-effects (e.g. impaired 
vasodilation), we can develop new approaches that work towards either reversing the 
progression atherosclerosis or restoring proper blood flow to ischemic tissues. 
 
Impact of Ischemia on Vasculature 
Impaired Vasodilation 
While PAD is becoming more prevalent throughout our population, the root of the 
problem is atherosclerosis and its co-morbidities (e.g. hypercholesterolemia) which are 
known to impair the vasculature. Atherosclerosis is a systemic disease, therefore patients 
with a clinical manifestation of a specific atherosclerotic disease (e.g. CAD) are likely to 
have pathologically similar lesions in other vascular beds. As eluded to earlier, patients 
who develop atherosclerotic occlusions experience impaired vasodilation in the collateral 
circuit [20].  This supports the hypothesis that atherosclerosis systemically affects the 
functional and morphological characteristics of several parts of the circulatory system.  
Although ischemic disease is associated with impaired vasodilation, an arterial occlusion 
alone also causes impairment [21]. This is supported by studies showing that vasomotor 
responses of relatively large collateral vessels to vasodilators are impaired in ischemic 
limbs of animal models in vivo[22]. 
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Vascular Smooth Muscle Phenotypes 
There is speculation that impaired vasodilation following arterial occlusion is due to 
arteriogenesis occurring in the collateral circuit. The transition of vascular smooth muscle 
cells from a differentiated (contractile) to a dedifferentiated (synthetic, migratory) 
phenotype plays a crucial role in the process of arteriogenesis. This phenotypic switch of 
SMCs also plays a critical role in many other physiological and pathological processes, 
including atherosclerosis, angiogenesis, smooth muscle hypertrophy, and hyperplasia 
[23]. Smooth muscle cells display a plastic diversity, meaning they dynamically exhibit 
distinct contractile and synthetic phenotypes with unique morphological, biochemical, 
functional, and gene expression characteristics [24]. The contractile smooth muscles are 
largely filled with contractile proteins and contain few subcellular organelles, while the 
synthetic smooth muscles have more subcellular organelles (e.g. free ribosomes and 
endoplasmic reticulum) involved in protein synthesis [25].  
As mentioned above, a marked difference is found in the expression of cytoskeletal and 
contractile proteins in these two phenotypes. Rabbit VSMCs can express at least three 
types of myosin heavy chain isoforms: SM1, SM2, and SMemb [25]. SM1 and SM2 are 
alternative RNA splicing products of a single gene and both are specifically expressed in 
SMCs. SM1 is constitutively expressed from early development, but SM2 only appears 
after birth. On the other hand, SMemb is predominantly expressed in embryonal and 
neonatal aortas but is down-regulated in adults [25].  In addition to its abundance in the 
brain vasculature, SMemb is expressed together with SM1 in SMCs undergoing growth 
and/or cell division, such as embryonic SMCs of fetal aorta and proliferating SMCs in 
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atherosclerotic neointima [26]. Based on these developmental characteristics, the myosin 
heavy chain profiles are most useful in defining smooth muscle cell differentiation as 
well as identifying abnormally proliferating smooth muscle cells in injured arteries [25]. 
VSMCs and their phenotypic transition are an integral step in the outward remodeling of 
collateral vessels. Prior to the synthesis of a new elastic lamina by VSMCs, MMPs digest 
the matrix and provide space for new cells and enable VSMCs to migrate toward the 
intima. Many non-proliferative VSMCs of the old media apoptose and are replaced by 
daughter cells of proliferative VSMCs [3]. Those that proliferate change their phenotype 
and degrade most of their contractile proteins, which are replaced by expanded 
endoplasmic reticulum and free ribosomes, an indication of their synthetic activity. The 
loss of the contractile phenotype is ascribed to the combined activities of protein kinase 
G, activin, and RGs-5 [3]. In addition to actin and myosin, desmin and calponin are 
downregulated and fibronectin is upregulated [3]. The thickening of the vessel wall 
occurs under markedly increased tangential wall stress causing the intercellular 
connections and the communication between cells to change. This is paralleled by the 
strongly induced expression of connexin 37 in VSMCs, which is an early marker for 
arteriogenesis that is normally not expressed in VSMCs and only weakly in endothelium 
[3].  
It is hypothesized that smooth muscle cell proliferation and migration, and the inability 
for the cells to relax and contract could be the reason for vascular impairment during a 
post-occlusion arteriogenic event.  
 
Introduction 
 
22 
 
Summary 
It is proficiently documented that patients with PAD or other ischemic diseases 
experience reduced blood flow to tissues distal of an atherosclerotic occlusion [10]. In 
addition to this, ischemic disease is typically coupled with an impaired vasculature 
characterized by reduced vascular reactivity [21]. In order to eventually understand the 
underlying mechanisms of dysfunction in patients with PAD, we must start by assessing 
vascular adaptations in simple animal models. This will help us determine the effects of 
the different responses to an arterial occlusion. We have chosen to study arteriogenesis 
first because it is thought to be critical for limb salvage and groups are currently trying to 
develop new therapies to stimulate this process. We hypothesize that smooth muscle 
cells, in their transition from a contractile to a synthetic state in response to vascular 
injury, are the cause of impaired vasoactivity observed in animal models. These studies 
will be a precursor for tailoring therapies to either stimulate vascular reactivity or to work 
around the area of impaired vasculature (i.e. arteriogenesis) in order to supply the 
ischemic tissue with adequate blood flow in patients with PAD. 
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Specific Aims 
In response to an arterial occlusion, arteriogenesis occurs, causing smooth muscle cells to 
transition from a contractile to synthetic state. Also following an arterial occlusion, 
functional impairment was seen in the collateral circuit. During this transition, smooth 
muscles cells proliferate and migrate, and in the process it is thought that they lose their 
ability to contract and relax efficiently. We hypothesize that this phenotypic transition of 
smooth muscle cells is the cause of impaired vasoactivity following arterial occlusion. 
We will assess the vasculature following an occlusion to understand the impact of 
arteriogenesis on smooth muscle proliferation. 
 Specific Aim 1 - Develop immunohistochemistry and immunofluorescence 
protocols to assess smooth muscle cell proliferation and determine vessel cross-
sectional area. 
 Specific Aim 2 - Determine the impact of an arterial occlusion on smooth muscle 
proliferation in the midzone and stem regions of the collateral circuit. 
 Specific Aim 3 - Determine the time dependence of smooth muscle proliferation 
and changes in vessel cross-sectional area in the collateral circuit. 
 
 
 
 
Methods 
 
24 
 
Methods 
Surgical Model 
Femoral Artery Ligation 
A femoral artery ligation surgery was performed to stimulate arteriogenesis in the 
superficial adductor collaterals of the house hind limb. To obtain an aseptic environment, 
surgical instruments and materials were autoclaved and the surgical field was disinfected 
with Novalsan. Refer to the appendix for specific instruments and sterile pack contents. 
  
The mouse was then weighed and placed into an anesthesia induction chamber where it 
was anesthetized with 5% isoflurane mixed with oxygen flowing at ~3 l/min. Once 
anesthetized, anesthesia was maintained with 1-3% isoflurane mixed with oxygen 
flowing at 0.5-1.0 l/min. An ear-hole punch was used for identification purposes (left ear, 
right ear, both ears, no ears). The hair on the left hind limb was removed with clippers 
and depilatory cream. The hind limb was then disinfected with Nolvasan and the animal 
was then given a subcutaneous injection of buprenorphine (0.075mg/kg) for analgesia. 
Figure 4 On the left is a diagram of the proximal ligation site, on the right is the surgery setup for a 
proximal ligation. 
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Once the animal was moved to the heat pad, a surgical anesthetic plane was maintained 
via a non-rebreathing nose-cone. Body temperature was maintained via rectal probe at 
37°C and veterinary ointment was applied to the eyes to avoid desiccation. 
A small incision was made in the middle medial aspect of the left thigh and extended up 
to the abdominal wall. Once surgical exposure was maximized, a heat cautery was used 
to resect the fat pad and the epigastric atrioventricular (a-v) pair. The femoral artery was 
blunt dissected from the neurovascular bundle, in between the profunda femoris and 
popliteal branches (See Figure 4). The femoral artery was tied off with a 6.0 silk suture 
and the incision was closed using a 7.0 polypropylene suture.  A contra-lateral sham 
control was prepared by making a similar incision in the middle, medial aspect of the 
right thigh and blunt dissecting the connective tissue. The incision on the sham limb was 
also closed with a 7.0 polypropylene suture. 
A second subcutaneous injection of buprenorphine (0.075mg/kg) was given for analgesia 
post surgery. Once ambulatory, the animal was placed in a new cage with surgery 
indicated on the cage card. 
Ventricular Catheterization and Perfusion Fixation 
Before the dissection, a vasodilator cocktail was prepared using heparin, adenosine, and 
sodium nitroprusside, and heated to 37°C. 
The mouse was then weighed and placed into an anesthesia induction chamber where it 
was anesthetized and prepared as described above. The animal’s limbs where then taped 
down to a heated bench cover and small incisions were made in the middle medial aspect 
of both hind limbs to visualize the femoral a-v pair and ensure proper vascular profusion. 
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The skin was removed from the abdomen up to the top of the thoracic cavity. A 20 mL 
syringe of the vasodilator cocktail was attached to a catheter and placed in the syringe 
pump. An incision was made in the abdomen over the xiphoid process and hemostats 
were clamped on the xiphoid process for handling of the thoracic wall prior to performing 
a thoracotomy (see Figure 5).  
 
 
 
 
 
 
A small incision was made in the apex of the heart and a catheter was  inserted into the 
left ventricle and clamped in place with a vascular clamp. The right atrium was also cut 
to allow drainage. Once catheterized, the vasculature was perfused with the vasodilator 
cocktail at 4 mL/minute. Next, 15 mL of histochoice was perfused to fix the vasculature 
in a dilated state (see Figure 6). 
 
 
Figure 5 Hemastats clamped on to exposed xiphoid process in 
preparation for entering the thoracic cavity. 
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The gracilis muscle and the profunda femoris artery were dissected from each hind limb 
and fixed in histochoice overnight. After post fixation, the tissue was stored in PBS at 
4°C. 
Histology 
Sample Preparation 
The tissue samples were dehydrated and impregnated with paraffin wax with a Shandon 
Excelsior ES tissue processor. Once processed, tissues were embedded in paraffin wax. 
The gracilis muscles were cut perpendicular to the muscle striations (exposing a cross-
section of the collaterals) and the profunda femoris artery was cut perpendicular to the 
longitudinal axis to obtain a vascular cross-section. The tissues were  placed with the 
medial aspect of the sample facing down in the cassette (so that the middle of the arteries 
would appear in the earlier sections). Once embedded, the tissue blocks were sectioned 
Figure 6 Correct catheter placement in the left ventricle for vascular 
perfusion. 
Methods 
 
28 
 
into 6μm sections using a Leica RM 2255 microtome. Tissue blocks were capped with 
hot wax and left to dry until the next use to minimize protein oxidation. 
Tissue Content Assessment 
Before immunostaining, tissue morphology was assessed using a standard hematoxylin 
and eosin stain (provided by Fisher Science). Once imaged, one can determine whether 
the tissue cross section is the correct orientation, whether the tissue contains vessels (in 
particular, gracilis collaterals or profunda femoris arteries), and whether these vessels 
were properly perfused, dilated and fixed. Once tissue morphology was assessed, the 
tissue blocks that contained pertinent vessels were marked for use in subsequent 
immunostains. 
 
 
 
 
 
 
 
 
 
Figure 7  Profunda femoris artery in the left hind limb 7 days after 
femoral artery ligation (designated by black arrow). 
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Immunohistochemistry 
Immunohistochemistry was used to detect proliferating smooth muscle cells, with 
peroxidase as the primary detection method. Tissues that contained pertinent vessels were 
sectioned with at least two samples on each slide (allowing for a negative control). The 
slides were placed into slide racks, and the paraffin was melted in an oven/incubator.  
The samples were then rehydrated in xylene, dehydrant, and distilled water and placed in 
an incubation chamber. Enzymatic antigen retrieval was performed with Promega 
Proteinase K and permeablization with 0.1% Triton X-100. After blocking non-specific 
protein binding with 1.5% donkey serum, proliferating smooth muscle cell nuclei were 
labeled with a Ki-67 primary antibody. A donkey anti-rabbit biotinylated antibody was 
used as the secondary detection method followed by the application of an avidin-biotin 
complex. A DAB-peroxidase substrate was used to give the positive tissues a brown 
precipitate. After dehydrating in dehydrant and xylene, samples were mounted and 
imaged using a bright-field microscope (See appendix for specific reagents, dilutions and 
incubation times). 
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Immunofluorescence 
Immunofluorescence was used to assess proliferating vs. non-proliferating smooth 
muscle cells, as well as vessel lumen areas in the gracilis collaterals and profunda femoris 
arteries. Tissues that contained pertinent vessels were sectioned, placed in slide racks, 
and then in an oven/incubator to melt the paraffin. The samples were then rehydrated in 
xylene, and dehydrant, and distilled water. 
The slides were then taken out of the slide racks and placed into an incubator. Enzymatic 
antigen retrieval was performed with Promega Proteinase K and permeablization with 
0.1% Triton X-100. After blocking non-specific protein binding with 1.5% donkey 
serum, proliferating smooth muscle cell nuclei were labeled by a Ki-67 primary antibody. 
An Invitrogen Alexa Fluor® 594 donkey anti-rabbit IgG was used as a secondary 
fluorescent detection method for the Ki-67. The sample was then stained with smooth 
muscle α-actin that was labeled with a Invitrogen Zenon® Tricolor Mouse IgG2a 
Figure 8 A gracilis collateral artery 7 days after femoral artery ligation stained 
with Ki-67. Proliferating smooth muscle cells show a brown precipitate. 
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Labeling Kit, allowing for the conjugation of a fluorescent complex to the α-actin 
primary antibody. Once the samples were post-fixed in 10% formalin, a nuclear counter-
stain was performed with BBI. The slides were then mounted and examined under the 
appropriate fluorescent light for imaging (see appendix for specific reagents, dilutions 
and incubation times). 
 
 
 
 
Figure 9 A Gracilis Collateral Artery 7 Days after a Femoral Artery Ligation. The collateral artery was 
stained with Ki-67 (green), smooth muscle alpha actin (red), and BBI (blue). 
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Morphology 
Imaging 
Three separate images were taken of each pertinent vessel in order to assess morphology. 
One image showing Ki-67 positive cells, another image showing smooth muscle α-actin, 
and a third showing cell nuclei (BBI) were all digitally captured. Once all samples were 
imaged, morphological measurements were taken using ImageJ, a free scientific imaging 
analysis software from the National Institutes of Health. An image of a 1mm micrometer 
was also taken at various magnifications in order to calibrate the measurement features in 
ImageJ.  
 
Vessel Cross-Sectional Area 
In order to make all measurements consistent, areas were taken from images of the 
vessels stained with smooth muscle alpha actin because these images gave the best 
contrast. This assumed that the endothelial cell layers of all the vessels were relatively the 
same thickness since the measurement starts deep to the intimal layer. Although this 
assumption may be inaccurate, measurements remained consistent among each other. 
Images were converted into a binary form in to allow for a semi-automated tabulation of  
luminal areas. 
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Figure 10 Images of normally stained SM alpha actin (green) and the binary form of the image used to take 
area measurements. 
Once the areas were tabulated for each vessel, they were entered into a Microsoft Excel 
spreadsheet under their respective tissue type and time point for further analysis. 
Cell Nuclei Counting 
Images of vessels displaying smooth muscle α-actin (green), Ki-67 (red) and BBI (blue) 
were merged to determine which cell nuclei were smooth muscle nuclei, and which of 
those smooth muscle cells were proliferating. Those nuclei immersed in green were 
deemed smooth muscle cell nuclei. If these smooth muscle nuclei had red staining around 
the edges or within the nuclei, it was deemed to be a proliferating nuclei cell. The amount 
of normal and proliferating smooth muscle cells were then counted for quantification. An 
example of smooth muscle phenotyping is shown in Figure 11. 
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Data Analysis 
Once the experimental data (vessel cross-sectional areas and vascular smooth muscle cell 
quantity) was gathered from each sample, a statistical analysis was performed using 
Microsoft Excel. A two-sample t-test (assuming unequal variances) was done, comparing 
data from the non-ligated and ligated samples for each time point (e.g. non-ligated vs. 
ligated gracilis cross-sectional areas for day 3, 7, 14). Two-sample t-tests were also used 
to compare the data from each time point for the profunda femoris versus the gracilis 
collaterals. Regression analysis and analysis of variance (ANOVA) was used to compare 
individual sets of data to their counterparts at the different time points (e.g. day 3 vs. day 
7 vs. day 14 ligated left gracilis cross-sectional areas). Statistical data was presented in 
mean ± standard error of the mean and statistical significance was determined by p < 0.05.  
Figure 11 Phenotyping of vascular smooth muscle cells in a gracilis 
collateral artery 3 days after femoral artery ligation. Non-proliferating 
smooth muscle cells are designated by the white arrows. Proliferating 
smooth muscle cells are designated by yellow arrows. 
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Results 
Vessel Cross-Sectional Area 
Cross-sectional area measurements were taken of the medial luminal area (this assumes 
that the endothelial cell layers of all the vessels are relatively the same thickness since the 
measurement starts at the media layer) for each vessel. Although vessel size appears to 
markedly increase as the post ligation period increased, a significant difference between 
the ligated and non-ligated areas was only seen at the day 7 and day 14 time points. A 
one way ANOVA for independent samples shows that the cross-sectional areas of the 
ligated gracilis collaterals for day 14  are significantly different than that of day 3 and day 
7 (see Figure 13).  
 
Figure 12 Progression of gracilis collateral enlargement over a two week period. Images chosen where 
those closest to the average in all groups. Vessel cross-sections were stained with smooth muscle α-actin 
(green). 
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The profunda femoris (muscular branch artery) showed a trend of increased cross-
sectional area as the post ligation time increased. However, although there was a trend of  
growth throughout the examined time periods, the cross-sectional areas of the ligated 
versus the contra lateral control was not significantly different for any time points (see 
Figure 15). 
 
Figure 13 Average gracilis collateral cross-sectional areas in ligated and non-ligated c57 hind limbs areas 
at 3, 7, and 14 days after femoral artery ligation. At day 7 and day 14 the areas are significantly different 
with p values of 0.0352( denoted by ▲) and 0.0007 (denoted by )respectively. A one-way ANOVA 
shows that day 14 ligated CSA is significantly different from day 3 and day 7(denoted by ■). 
Figure 14 An average sham (day 0) profunda femoris artery (left)  and a profunda 
femoris artery 14 days after a femoral artery ligation (right). Images chosen where those 
closest to the average in both groups. Vessel cross-sections were stained with smooth 
muscle α-actin (green). 
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Figure 15 Average profunda femoris cross-sectional areas in ligated and non-ligated c57 hind limbs at 3, 7, 
and 14 days after femoral artery ligation. Although there was an increasing trend in the average area of the 
vessels in the ligated legs, no significant difference was seen between the ligated and contra lateral control. 
When comparing the cross-sectional areas of the ligated gracilis collateral and profunda 
femoris arteries it appears that the gracilis collaterals generally approach the relative size 
of the profunda femoris arteries. A t-test shows that the profunda femoris and gracilis 
collateral cross-sectional areas are significantly different in day 3. Although the 
difference between the averages of the gracilis collateral and profunda femoris arteries is 
larger in day 7 than it is in day 3, a t-test showed that the day 7 averages were not 
significantly different. Figure 6 shows that the cross-sectional area of the gracilis 
collaterals approaches that of the profunda femoris over the two week period. 
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Figure 16 Progression of gracilis collaterals (top row) and profunda femoris arteries 
(bottom row) from day 0 (left column) to day 14 (right column). Images used were 
those with areas closest to the average. Vessel cross-sections were stained with 
smooth muscle α-actin (green). 
Figure 17 The average gracilis collateral vs. profunda femoris cross-sectional areas in ischemic c57 hind 
limbs at 3, 7, and 14 days after femoral artery ligation. A t-test with a p-value of 0.002 (denoted by ) 
shows that the areas of the two arteries are significantly different at day 3. 
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Vascular Smooth Muscle Cell Quantification 
Total Smooth Muscle Cell Count 
The total number of vascular smooth muscle cells (VSMCs) present in each vessel was 
tabulated. In the gracilis collaterals, there was an increasing trend in the average number 
of VSMCs in the ligated samples. However, only days 3 and day 14 showed a significant 
difference between the ligated and contra lateral control. Although a one-way ANOVA 
gave a p-value of 0.0411, the difference between the averages in the ligated gracilis 
collaterals at day 3, day 7, and day 14 were deemed non-significant. 
 
Figure 18 The average number of vascular smooth muscle cells in the gracilis collaterals in ligated and 
non-ligated hind limbs. The average number of smooth muscle cells was significantly different at day 3 and 
day 14, with p-values of 0.0128 (denoted by ▲) and 0.0002 (denoted by ), respectively. 
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As for the profunda femoris arteries, there was little variation between the ligated and 
non-ligated groups. None of the time points showed a significant difference when 
comparing the ligated with the non-ligated hind limb (see Figure 19). 
 
Figure 19 The average number of vascular smooth muscle cells in the profunda femoris arteries in ligated 
and non-ligated hind limbs. None of the time points showed a significant difference when comparing the 
ligated and non-ligated data. 
When comparing the quantity of VSMCs in gracilis collaterals and profunda femoris 
arteries, all time points showed a significant difference. Although all p-values were under 
0.05, the day 3 and day 7 time points were more significantly different than that of day 14 
(see Figure 20). 
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Figure 20 The average number of VSMCs in the gracilis collaterals and profunda femoris arteries in the 
ligated c57 hind limbs. Days 3 and 7 gave p-values less than 0.01 (0.0032 and 0.0098 respectively, denoted 
by ) and day 14 gave a p-value less than 0.05 (p=0.01, denoted by ▲). 
Smooth Muscle Cell Phenotype 
The only samples that stained positive for Ki-67 were the gracilis collaterals at day 3 and 
day 7 following a femoral artery ligation. This signifies that smooth muscle cells were 
proliferating at day 3 and day 7, but not day 14. There was an average of 1.6 and 2.5 
proliferating VSMCs at day 3 and day 7 respectively. A t-test showed that the amount of 
proliferating VSMCs present at day 3 and day 7 are significantly different than those 
found at day 0 (sham) and day 14. The line graph shown in Figure 22, shows the 
progression of the proliferating VSMCs over the two week period. 
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Figure 21 Progression of the gracilis collaterals over the two week post-ligation period. Vessels chosen 
were those that had the closest areas and amount of VSMCs to the averages in each group. Each vessel was 
stained with smooth muscle α-actin (green), the Ki-67 proliferation marker (red), and BBI for the nuclei 
(blue). 
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Figure 22 Average number of proliferating smooth muscle cells in ligated gracilis collateral arteries. A t-
test showed that days 3 and 7 were significantly different from day 0 and day 14 with a p-value less than 
0.005 (p = 0.0003, 0.0033 for day 3 and day 7 respectively). 
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Discussion 
Time Dependence of Smooth Muscle Cell Phenotype 
The gracilis collaterals experienced arteriogenesis following a femoral artery ligation in 
the C57 mouse hind limb, Figure 21. Evidence of this was supported by the fact that the 
smooth muscle cells that were positive for Ki-67 at 3 and 7 days and collaterals 
significantly enlarge over the two week period following the ligation. Although smooth 
muscle cells were quantified, we mainly wanted to show that proliferation was observed 
at day 3 and day 7, but not at day 0 and day 14. To obtain a more accurate quantification 
in the future, imaging exposure times, incubations periods, and procedural conditions 
must remain consistent in order to use implications, such as fluorescent intensity, as an 
indication of quantity.  
Since the Ki-67 protein is expressed during all active phases of the cell cycle and the 
rapid disappearance of the Ki-67 antigen is associated with a non-proliferative (inactive) 
state of any part of the cell cycle [27], we can also postulate that SMCs positive for Ki-67 
are proliferating, or in a synthetic state. Although there was a trend of more proliferation 
at day 7, a one-way ANOVA shows that the average amounts of proliferating VSMCs 
present at days 3 and 7 are not significantly different. 
These findings were somewhat consistent with previous work. The first positive Ki-67 
reaction (i.e. proliferating cells) in the vessel wall of the growing collaterals in New 
Zealand white rabbits was found 24 hours after the occlusion in the mid-zone of the 
collaterals of the quadriceps [28]. The Ki-67 reaction increased up to day 3, however 
proliferation diminished in the collaterals at days 7 and 21 [28].  
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Previous work in mice was also used to distinguish the different phases of remodeling 
during arteriogenesis. The first, proliferative phase of arteriogenesis occurs 1-3 days after 
occlusion, and is characterized by a maximal mitotic activity in the endothelial cells, 
SMCs, and fibroblasts [28]. The next stage is the synthetic/growth phase (3-14 days) that 
is characterized by reduced mitosis and initiation of synthetic and proteolytic activity in 
SMCs [28]. During this time the internal elastic lamina is digested and fragmented by the 
elastolytic enzymes to facilitate positive remodeling by the SMCs [28]. Although the 
previous work was done in New Zealand white rabbits, the time course is similar to that 
of our study. 
Previous work also characterized the proliferation phase as 1-3 days after occlusion [29]. 
Three days after femoral occlusion in the mouse hind limb, remodeling is characterized 
by swollen endothelium, disrupted elastic lamina, mitotic phenotypes in both smooth 
muscle and endothelial cells (evidenced by endothelial and smooth muscle cells taking up 
BrdU and Ki-67 labeling) [6]. The period from 3 days to 2 weeks is defined as the 
synthetic phase and is characterized by high proliferation activity at the beginning of the 
phase, followed by the first recovery of blood flow to the ischemic limb after 7 days [29]. 
The vessel's ultrastructure returned to normal 7 to 14 days after occlusion, and the BrdU 
and Ki-67 labeling decreased [6]. Then, after 10 to 14 days proliferation activity 
diminishes and SMCs gradually return to the contractile phenotype [29]. 
Although my results were similar to previous work, this study only measured 
proliferation in the SMCs, so another cogitation to be considered about this study is the 
distinction between a proliferating and a synthetic smooth muscle cell. Since only 
proliferating smooth muscle cells were assessed, we want to know what allotment of 
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those cells were in a "synthetic" state as well. Smooth muscle cells dynamically exhibit 
distinct contractile and synthetic phenotypes with unique morphological, biochemical, 
functional, and gene expression characteristics [24]. The plasticity of the length-tension 
properties and the organization of contractile filaments in smooth muscle further extends 
the functional diversity of SMCs [24]. These observations tell us that there is a full 
spectrum of SMC function, dictated by phenotypic and mechanical plasticity, that is 
controlled by molecular mechanisms [24]. 
Although SMCs are on a plastic continuum, cells in the contractile state are deemed non-
proliferative, evidenced by the fact that this phenotype is that of a differentiated cell. This 
is not to say that contractile smooth muscle cells have zero proliferation, but that there is 
a minimal rate of proliferating and a balance in the production and degradation of 
proteins [30]. According to Scholz et al., although proliferation appears to peak at day 3, 
it is present for up to three weeks, which encompasses the synthetic activity period in the 
SMC (3 to 14 days) [28]. From this, we can postulate that Ki-67 positive smooth muscle 
cells from day 3 to day 14 is of a synthetic nature.  
Impact of Location on the Collateral Circuit 
Although we saw proliferation in the gracilis collaterals, the mid-zone of the collateral 
circuit, there was no proliferation seen in the profunda femoris (muscular branch)  
arteries, the stem region of the collateral circuit, at any of the time points. However, 
following the femoral artery ligation, the average cross-sectional area of the profunda 
femoris experienced an increasing trend over the two week period. While an increasing 
trend was seen, a t-test on all three time points showed that none of the average areas 
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were significantly larger than the non-ligated samples. A one-way ANOVA also 
demonstrated that the average areas at the post ligation time points were not significantly 
different, nor were the non-ligated time points. Although no significant difference was 
seen in this study, previous work does show a significant difference at certain time points. 
 Despite observing no proliferation or a significant increase in profunda femoris cross-
sectional area, it has been well documented that an arterial occlusion can lead to impaired 
vasoactivity in the stem region of the collateral circuit. Proliferating smooth muscle cells 
seen after an occlusion could explain abnormal functional dilation in the gracilis 
collaterals. However, we found no proliferating SMCs in the profunda at any time after 
the occlusion, leading us to believe that the impaired vasodilation may be caused by other 
changes in smooth muscle phenotype or may not be smooth muscle dependent. 
Two previous studies on the impact of vascular occlusion on vascular reactivity through 
femoral artery ligation showed cross-sectional area measurements that were inconsistent 
with those of this study. The vessel diameter measurements for the previous studies were 
taken via in vivo intravital microscopy and because the vessel measurements for this 
study were taken via histological analysis, there are expected discrepancies between the 
two sets of data. 
Our group measured cross-sectional areas (assuming a perfectly cylindrical vessel) 3 days 
after the same proximal femoral artery ligation and saw no significant difference between 
vessel diameters of the ligated and non-ligated profunda femoris arteries. Although the 
areas tabulated from this study (ligated profunda CSA ≈ 2,551 µm2, non-ligated profunda 
CSA ≈ 1654 µm2)  and my own (L = 1643 µm2, NL = 2176 µm2) are slightly different, 
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the overall data for this time point was consistent between the two. Our group also 
measured two sets of day 7 cross-sectional areas, which yielded different results from the 
measurements of this study. The first set of cross-sectional area measurements of the 
ligated profunda femoris (≈ 3525 µm2) was significantly larger (p-value < 0.05) than that 
of the non-ligated profunda femoris (≈ 1978 µm2) 7 days post occlusion. The second set 
of measurements also yielded a significant difference (p-value < 0.01)  in the cross-
sectional areas of the ligated (≈ 7853 µm2) and non-ligated (≈ 1963 µm2) profunda 
femoris arteries. Although the measurements are within reasonable range of my own (L = 
1789 µm
2
, NL = 1568 µm
2
), there was a statistical difference present that did not occur in 
this study. Previous measurements by our group also showed a significant difference (p-
value < 0.01) between the ligated (≈ 6361 µm2) and the non-ligated (≈ 2375 µm2) 
profunda femoris arteries 14 days after occlusion. Similar to the day 7 study, the non-
ligated profunda femoris (= 1664 µm
2
) from this study is within range, but the ligated 
profunda femoris (= 2239 µm
2
) was much smaller and there was no significant difference 
between the two. 
There are many physiological and experimental factors that could have attributed to the 
substantial differences seen in the ligated profunda femoris measurements, especially in 
the day 7 and day 14 studies. The main source of inconsistencies was most likely the 
different methods of vessel measurement. Intravital microscopy measurements from the 
previous two studies were taken in vivo when the vasculature was in a resting state. In 
this study, the vasculature was perfused with a vasodilator and immediately perfused with 
a fixative to achieve a maximal resting diameter. However, ventricular catheterization is a 
delicate procedure. At times, only the arterial side would perfuse or the vasodilator would 
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barely perfuse the vasculature at all (due to improper catheter placement, puncture of the 
ventricular septum, clotting, etc.). Because of this, not all vessels were fixed in a fully 
dilated state. Also, to examine samples histologically, the tissues must be processed, a 
procedure that tends to substantially shrink the tissues. 
Aside from the different methods of taking vessel measurements, another source of error 
could have originated from the ligation procedure. Although each surgeon followed the 
same procedure for the proximal femoral artery ligation, inconsistencies can still occur. 
For instance, if there were branch points proximal to the ligature and distal to the 
profunda, there would be a reduced shear on the profunda, which may have had an effect 
on the results obtained. 
Although different results were obtained from this study and previous similar studies, the 
overall trend shows an enlargement of the profunda post occlusion. This is expected 
because of the increased blood flow in the profunda femoris when the femoral artery is 
occluded. Although the profunda increases in diameter, impaired functional vasodilation 
was only seen in one of the two studies on the effects of vascular occlusion. The other 
study showed that the ligated and non-ligated profundas dilated relatively the same 
percent when stimulated. 
The next logical step would be to take the same intravital measurements at 3, 7 and 14 
days post ligation to confirm the presence of a functional vasodilation impairment. If no 
impairment is observed, this would support the hypothesis that smooth muscle 
proliferation is necessary to induce impaired vasodilation. Since the vessel did not 
contain proliferative cells, if impaired dilation is observed, it is possible that the 
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impairment was due not to proliferation, but an acute mechanoadaptation, which may 
have occurred to cause the profunda to enlarge following the occlusion. In response to 
prolonged constriction, VSMCs undergo a mechanoadaptation process involving "length 
autoregulation" that would be energetically favorable for maintenance of a reduced vessel 
diameter [31].  This process involves cellular repositioning of the VSMCs in the presence 
of the maintained constriction[31]. Although this phenomenon has mostly been witnessed 
in vessels exposed to prolonged vasoconstriction, studies have shown that prolonged 
vasodilation can also cause acute outward remodeling [32]. Although there is no evidence 
that the SMCs in the profunda experienced this acute mechanoadaptation following the 
ligation, this could explain why the vessel enlarged over the two week period in all three 
studies, without proliferation, and may explain any confirmed impairment in functional 
vasodilation. While the smooth muscle cells do not change phenotypes during this 
mechanoadaptation, it is possible that a transient reduction in smooth muscle function 
could have occurred due to the reconstitution of the extracellular matrix and the 
repositioning of the smooth muscle cells.  
To test this hypothesis we would  measure vascular reactivity to endothelial and smooth 
muscle dependent agents using intravital microscopy. This would initially involve the 
same surgical procedure as the previous experiments in which a ligation surgery would 
be performed on at least six mice for each time point (day 3, day 7, day 14). At each time 
point the mice would undergo a superfusion procedure in which smooth muscle and 
endothelial dependent dilators (e.g. sodium nitroprusside and acetylcholine) would be 
placed over the profunda while diameter measurements are taken simultaneously via 
intravital microscopy. If the profunda does not respond to endothelial or smooth muscle 
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dependent dilators, then the aforementioned hypothesis of a transient reduction in smooth 
muscle function due to a mechanoadaption would be supported. If the profunda only 
responds to smooth muscle and not endothelial dependent dilators, then this would 
support the hypothesis that the impairment is endothelial dependent.  
 
Although impaired vascular function is not likely a result of smooth muscle cell 
proliferation in the profunda, as mentioned above, it is possible that SMCs are the cause 
of vascular impairment in the gracilis collaterals. The gracilis collaterals enlarged over 
the two week period following a femoral artery ligation. A t-test shows that the average 
cross-sectional areas from day 7 (= 805 µm
2
)   and day 14 (= 2237 µm
2
) are significantly 
different from that of day 0 averages (= 417 µm
2
), with p-values of 0.0352 and 0.0007 
respectively. Also, a one-way ANOVA showed that the average CSA at day 14 was 
significantly different from that at days 3 and 7. This data is consistent with many other 
studies in which we see significant collateral growth over a two week time period 
following an upstream arterial occlusion. 
Since SMCs were proliferating at day 3 and day 7 following a ligation in the gracilis 
collaterals, the next logical experimental step would be to examine vascular function in 
this region of the collateral circuit following an occlusion. This experiment would require 
the use of a multiphoton fluorescence microscope, as the gracilis collaterals are too deep 
to examine via traditional intravital microscopy. At each time point following the ligation 
surgeries (day 3, day 7, day 14), fluoropores would be injected into the vasculature in 
order to make the collaterals visible via fluorescent microscopy. Once visible, functional 
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measurements can be taken following the application of SNP and acetylcholine to 
determine the functionality of both endothelial and smooth muscle cells. If there is little 
functional response to SNP and these responses parallel the same time course as smooth 
muscle proliferation, this would strongly suggest that vascular impairment is smooth 
muscle dependent in the gracilis collaterals following a ligation.  
 
Conclusions 
At days 3 and 7 following a femoral artery ligation, we observed proliferating smooth 
muscle cells in the gracilis collaterals as well as significant collateral vessel growth over 
a two week period. This study correlated well with previous studies in that proliferation 
followed a similar time course, and significant vessel growth was observed. As 
mentioned above, the next logical step would be to determine if the time course of 
proliferation parallels with functional impairment in the gracilis collaterals. If there is a 
parallel, then this would strongly suggest that the impairment in the gracilis collaterals is 
due to smooth muscle dysfunction during their phenotypic transition. 
Following the same ligation we did not observe any proliferation in the profunda femoris 
and although there was an increasing trend in vessel size over the two week period, none 
of the averages were significantly different. These results differed from those of previous 
studies performed within the lab group. The previous studies also differed in that one 
study observed impairment and one did not.  For this reason, the next step should be to 
make functional measurements again to determine if there is impairment in the profunda 
after a ligation. If there is no impairment then my results would make sense, since there is 
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no SMC proliferation. If there is impairment, then we know that smooth muscle cell 
proliferation is not the cause, and further tests need to be done to find the cause of this 
vascular dysfunction. 
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Appendix 
 
 Protocols 
 
Femoral Artery Ligation Protocol 
Materials 
Sterilize- autoclave or flash autoclave 
____1. forceps (2) 
____2. fine forceps (2) 
____3. ultrafine forceps (1) 
____4. fine scissors (1) 
____5. microscissors spring loaded (1) 
 
Pre-sterilize in autoclave 
____6. cotton gauze (2) 
____7. cotton swabs (12) 
____8. 6.0 silk suture (2 x 1-inch) 
____9. needle holder (1) 
 
Obtained in surgery suite 
____10. sterile Petri dish w/ sterile saline 
____11. sterile gloves 
____12. sterile 7.0 prolene suture 
____13. heat-cautery 
____14. FST heat pad w/ rectal probe 
____15. heat pad 
____16. recovery bin & weigh boat 
____17. depilatory cream 
____18. non-sterile cotton swabs 
____19. non-sterile cotton gauze 
____20. isolation mask & cap 
____21. analgesic (Buprenorphine) 
 
Surgery preparation 
____22. Spray surgery area with Nolvasan 
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____23. Weigh animal in weight boat 
____24. Place animal in anesthesia box 
____25. Open the oxygen cylinder and set anesthesia-machine flow meter to ~3 l·min-1 
____26. Anesthetize animal w/ 5% isoflurane  
____27. Affix non-rebreathing circuit to bench-top with tape  
____28. Reduce flow rate to 0.5-1.0 l·min-1 and the isoflurane to 1-3% 
____29. Apply ear tag high on left ear 
____30. Lay animal supine with nose in nose-cone 
____31. Shave hair on the right hindlimb & lower abdomen with clippers  
____32. Remove excess hair with depilatory cream 
____33. Spray right hindlimb with Nolvasan 
____34. Return animal to anesthesia box 
 
 
____35. Apply 4x4 gauze sponge to heat pad to protect animal from excessive heat 
____36. Affix non-rebreathing circuit to surgery table w/ chemistry clamp 
____37. Lay animal supine on circulating heat pad w/ nose in nose-cone 
____38. Insert rectal probe and set thermo-controller to 37°C 
____39. Apply veterinary ointment to eyes to avoid drying during procedure 
____40. Apply veterinary ointment to anus and place rectal probe ~1cm into anus to 
monitor core-body temperature 
 
Surgery 
____41. Make a small incision on the middle, medial aspect of the left thigh 
____42. Extend the incision up to the abdominal wall  
____43. Blunt dissect the subcutaneous connective tissue to maximize surgical 
exposure 
____44. Use cautery to remove fat pad overlying femoral a-v pair & cauterize 
epigastric av-pair 
____45. Blunt dissect the femoral artery from the neurovascular bundle just 
downstream from the deep femoral branch 
____46. Tie off the femoral artery & vein with 6.0 silk suture, just downstream to the 
deep femoral branch 
____47. Use 6.0 polypropylene suture to close the skin  
____48. Make a small incision on the middle, medial aspect of the right thing 
____49. Extend the incision up to the abdominal wall 
____50. Blunt dissect the subcutaneous connective tissue to maximize surgical 
exposure 
____51. Use 6.0 polypropylene suture to close the skin  
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Post-Surgical  
____52. Give the animal an subcutaneous injection of buprenorphine (0.075mg/kg) 
____53. Place the animal in the recovery bin, on a blue bench cover, above a heat pad 
and allow to recover 
____54. Turn flow meter down to 0, turn off isoflurane, and close the oxygen cylinder 
____55. Indicate surgery on cage card 
 
 
Perfusion Fixation Protocol 
 
Materials 
Non-Sterilize Dissection Instruments 
____56. forceps (2) 
____57. fine forceps (2) 
____58. Bone Scissors(1) 
____59. Skin Scissors (1) 
____60. Dissection Scissors (1) 
____61. Hemostats(1) 
____62. Vascular clamp (1) 
 
Obtained in surgery suite 
____63. Tape 
____64. 10mL Syringes (2) 
____65. Bench cover 
____66. Heating pad 
____67. Catheter 
____68. Avertin Anesthetic 
____69. Non-sterile saline 
____70. Cotton swab 
 
Vasodilator Cocktail Preparation 
____71. Turn on water bath to 37ºC 
____72. 400 µL heparin  
____73. 1mL SNP(orange) 
____74. 600µL Adenosine(clear) 
____75. 38mL PBS solution 
____76. Thaw SNP and Adenosine 
____77. Add heparin, SNP, Adenosine, and PBS solution together in a 50mL conical 
____78. Place vasodilator cocktail in water bath 
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____79. Prepare 15mL of histochoice in a 50mL conical and place in water bath 
 
Procedure Preparation 
____80. Weigh animal and draw up appropriate dose of Avertin anesthetic 
(.15mL/10g) 
____81. Obtain saline filled beaker, cotton swab, and instruments  
 
Fixation 
____82. Anesthize mouse with Avertin 
____83. Heat up heat pad in microwave and wrap with bench cover when warm 
____84. Remove hindlimb hair on both legs by shaving  
____85. Tape animal down to heated bench cover 
____86. Separate skin from muscle from the abdomen to the top of the thoracic cavity 
____87. Fill 10mL syringe with warm Vaso D 
____88. Cut through abomen close to diaphragm 
____89. Quickly cut through the ribs and diaphragm to open chest cavity and clamp 
back with hemostats 
____90. Cut away excess tissue around the heart 
____91. Make a small incision in the apex of the heart 
____92. Insert catheter and clamp with vascular clamp and cut right ventricle 
____93. Inject Vaso D solution into animal approximately 20mL  
____94. Inject 12mL of histochoice 
____95. Dissect the muscular branch and gracilis muscle preserve in histochoice  
 
  
Ki-67 Immunohistochemistry Protocol 
 
Materials 
Histology Components 
____96. Microscope slides 
____97. Staining dishes (4) 
____98. Incubating chamber 
____99. Hydrophobic pen 
____100. Microscope slide rack 
____101. Hemostats 
____102. Mounting Medium 
____103. Cover slips 
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Reagents Checklist (See protocol appendix for reagent preparation) 
____104. Xylene 
____105. 100% EtoH 
____106. 95% EtoH 
____107. Distilled Water 
____108. Phosphate Buffered Saline 
____109. Promega Proteinase K* 
____110. PBST* 
____111. Hydrogen Peroxide (H2O2) 
____112. Blocking Serum* 
____113. Ki-67 primary antibody* 
____114. Biotinylated secondary antibody* 
____115. AB Enzyme* 
____116. Peroxidase Substrate* 
 
Sample Preparation and Rehydration 
____117. Section desired number of blocks on a desired number of slides 
____118. Place slides in a slide rack and put in oven/incubator and turn dial to “7” and 
remove when wax has melted 
____119. While was is melting, prepare four staining dishes with the following 
reagents: xylene, 100% EtoH, 95% EtoH, and distilled H20. 
____120. When wax is melted, place slide rack in xylene dish for 10 minutes. 
____121. Place slides in 100% EtoH for 2 minutes (x2). 
____122. Place slides in 95% EtoH for 2 minutes. 
____123. Place slides in distilled for 2 minutes. 
 
Staining Procedure 
____124. Remove slides one by one from distilled water, circle samples with 
hydrophobic pen, and place in incubator. 
____125. Incubate samples in Proteinase K working solution for 10 minutes. 
____126. Wash with PBS for 5 minutes. 
____127. Incubate in PBST for 15 minutes. 
____128. Wash with PBS for 5 minutes. 
____129. Block non-specific peroxidase binding with H2O2 for 10 minutes. 
____130. Wash with distilled H2O for 5 minutes. 
____131. Block samples with blocking serum for 30 minutes. 
____132. Apply Ki-67 primary antibody to one sample on the slide (leaving only 
blocking serum on the other sample for a positive control) and incubate over 
night at 4°C. 
____133. Wash with PBS for 5 minutes 
____134. Incubate in biotinylated secondary antibody for 30 minutes 
____135. Immediately after applying secondary antibody, prepare AB enzyme. 
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____136. Wash with PBS for 5 minutes 
____137. Apply AB enzyme and incubate for 30 minutes 
____138. Wash with PBS for 5 minutes 
____139. Apply peroxidase substrate and incubate for 5 minutes 
____140. Wash slides in distilled H2O 
____141. Dip slides in 95% EtoH for 10 seconds (x2) 
____142. Dip slides in 100% EtoH for 10 seconds (x2) 
____143. Dip slides in xylene for 10 seconds (x3) 
____144. Mount slides with mounting medium and allow them to dry over night. 
 
Reagent Preparation 
All working solutions can be stored @ 4°C for 2-3 weeks unless otherwise specified. 
Proteinase K working solution:  
Use Promega Proteinase K (Specific Activity: 30u/mg) and dilute 1:500 in PBS.  
 
Phosphate Buffered Saline /w Triton X-100(PBST): 
Use 1% Triton x-100 in PBS (i.e. .05mL of Triton 
X-100 in 5mL of PBS) 
 
Blocking Serum: 
Use the same blocking serum in which your  
secondary antibody was raised (i.e. if you’re using a  
donkey anti-rabbit secondary antibody, use 
donkey blocking serum). Add 75μL of blocking  
serum stock to 5 mL of PBST for blocking serum  
working solution. 
 
Ki-67 Primary antibody: 
Use Abcam Ki-67 rabbit polyclonal primary  
antibody (ab15580), use a 1:200 dilution in  
blocking serum working solution (i.e. 10μL of  
primary antibody stock in 2mL of blocking serum  
working solution). 
 
Biotinylated Secondary antibody: 
Since primary antibody is a rabbit polyclonal,  
use an “anti-rabbit” secondary antibody (i.e.  
donkey anti-rabbit). For working solution add 75μL  
of blocking serum stock and 25μL of secondary  
antibody stock to 5mL of PBS. 
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AB Enzyme: 
Use Vector Labs Vectastain Elite ABC reagent. For  
working solution, add two drops of Reagent A, and  
two drops of Reagent B to 5mL of PBS, mix  
immediately and allow ABC reagent to stand for  
about 30 minutes before use. 
 
Peroxidase Substrate: 
Prepare substrate before use every time, do not  
store. For working solution add one drop of  
peroxidase substrate, one drop of DAB chromagen,  
and 5 drops of 10x substrate buffer to 1.6mL of  
distilled water. 
 
Smooth Muscle Cell Phenotyping Immunofluorescence Protocol 
Materials 
Histology Components 
____145. Microscope slides 
____146. Staining dishes (4) 
____147. Incubating chamber 
____148. Hydrophobic pen 
____149. Microscope slide rack 
____150. Aluminum Foil 
____151. Hemostats 
____152. Cover slips 
 
Reagents Checklist (See Appendix for reagent preparation) 
____153. Xylene 
____154. 100% EtoH 
____155. 95% EtoH 
____156. Distilled Water 
____157. Phosphate Buffered Saline 
____158. Promega Proteinase K* 
____159. PBST* 
____160. Blocking Serum* 
____161. Ki-67 primary antibody* 
____162. Ki-67 fluorescent anti-rabbit secondary antibody* 
____163. SM α-actin fluorescent complex** 
____164. 10% Formalin 
____165. BBI* 
____166. Fluorescent mounting medium 
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Sample Preparation and Rehydration 
____167. Section desired number of blocks on a desired number of slides 
____168. Place slides in a slide rack and put in oven/incubator and turn dial to “7” and 
remove when wax has melted 
____169. While wax is melting, prepare four staining dishes with the following 
reagents: xylene, 100% EtoH, 95% EtoH, and distilled H20. 
____170. When wax is melted, place slide rack in xylene dish for 10 minutes. 
____171. Place slides in 100% EtoH for 2 minutes (x2). 
____172. Place slides in 95% EtoH for 2 minutes. 
____173. Place slides in distilled for 2 minutes. 
 
Staining Procedure 
____174. Remove slides one by one from distilled water, circle samples with 
hydrophobic pen, and place in incubator. 
____175. Incubate samples in Proteinase K working solution for 10 minutes. 
____176. Wash with PBS for 5 minutes. 
____177. Incubate in PBST for 15 minutes. 
____178. Wash with PBS for 5 minutes. 
____179. Block samples with blocking serum for 30 minutes. 
____180. Incubate in Ki-67 primary antibody over night at 4°C 
____181. Wash with PBS for 5 minutes 
____182. Cover incubator in aluminum foil to protect from the light for rest of 
procedure 
____183. Incubate in Ki-67 fluorescent anti-rabbit secondary antibody for 90 minutes 
____184. Wash with PBST for 5 minutes 
____185. Incubate in SM α-actin fluorescent complex for 45 minutes 
____186. Wash with PBST for 10 minutes (x3) 
____187. Wash with PBS for 5 minutes (x2) 
____188. Fix samples with 10% formalin for 15 minutes 
____189. Wash slides with PBS 
____190. Incubate samples in BBI for 10 minutes 
____191. Wash slides with PBS 
____192. Mount slides with fluorescent mounting medium, protect them from light, and 
allow them to dry over night 
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Reagent Preparation 
*All working solutions can be stored @ 4°C for 2-3 weeks unless otherwise specified. 
**SM α-actin fluorescent complex needs to be used within 30 minutes of preparing it. 
Proteinase K working solution:  
Use Promega Proteinase K (Specific Activity: 30u/mg) and dilute 1:500 in PBS.  
Phosphate Buffered Saline /w Triton X-100 (PBST): 
Use 0.1% Triton x-100 in PBS (i.e. .05mL of Triton X-100 in 50mL of PBS) 
 
Blocking Serum: 
Use the same blocking serum in which your  
secondary antibody was raised (i.e. if you’re using a  
donkey anti-rabbit secondary antibody, use 
donkey blocking serum). Add 75μL of blocking  
serum stock to 5 mL of PBST for blocking serum  
working solution. 
 
Ki-67 Primary antibody: 
Use Abcam Ki-67 rabbit polyclonal primary  
antibody (ab15580, Lot #GR21314-1) , use a 1:200  
dilution in blocking serum working solution (i.e.  
10μL of primary antibody stock in 2mL of blocking  
serum working solution). 
 
Ki-67 fluorescent anti-rabbit secondary antibody: 
Since primary antibody is a rabbit polyclonal,  
use an “anti-rabbit” secondary antibody (i.e.  
donkey anti-rabbit). For working solution dilute  
anti-rabbit fluorescent secondary antibody 1:1000 in  
blocking serum working solution (i.e. add 5μL of  
fluorescent 2° ab to 5mL of donkey serum in  
PBST). 
 
SM α-actin fluorescent complex: 
**Complex must be used with in 30 minutes of preparing it. For 10 slides, add 10μL of 
sm α-actin to 0.5mL of PBS. Add 5μL of the desired color of the Zenon labeling 
component, shake, and incubate for 5 minutes. Add 5μL of Zenon blocking serum, shake 
and incubate for 5 minutes. Add .5mL of blocking serum working solution. Use within 30 
minutes. 
 
BBI fluorescent nuclear stain: 
Dilute BBI stock 1:1000 in 18mΩ H2O (i.e. 10μL of BBI in 10mL of 18mΩ H2O). 
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Vessel Morphology and Phenotype Raw Data 
Day 3 
Ligated Left 
Gracilis 
   
Block Number 
Cross-Sectional 
Area (μm2) 
Proliferating 
Smooth Muscle 
Cell Count 
Smooth Muscle 
Cell Count 
11-222 a 486.4 1 2 
11-222 b 441.2 2 5 
11-230 a 735.3 0 3 
11-230 b 1928.9 2 6 
11-234 a 697.1 3 3 
11-234 b 630.4 2 4 
11-238 a 867.2 2 3 
11-238 b 257.9 1 2 
11-242 455.2 1 2 
Average 722.1777778 1.555555556 3.333333333 
Standard 
Deviation 488.3396456 0.836660027 0.836660027 
Standard Error 162.7798819 0.278886676 0.278886676 
 
Ligated Left 
Muscular Branch 
   
Block Number 
Cross-Sectional 
Area (μm2) 
Proliferating 
Smooth Muscle 
Cell Count 
Smooth Muscle 
Cell Count 
11-223 1735.2 0 8 
11-227 2008.1 0 12 
11-231 1965.8 0 6 
11-235 1750.1 0 10 
11-239 639.4 0 4 
11-243 1764.1 0 9 
Average 1643.783333 0 8.166666667 
Standard 
Deviation 505.8346742 0 2.857738033 
Standard Error 206.506141 0 1.166666667 
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Non-Ligated 
Right Gracilis 
Block Number 
Cross-Sectional 
Area (μm2) 
Proliferating 
Smooth Muscle 
Cell Count 
Smooth Muscle 
Cell Count 
11-178 553.7 0 1 
11-224 259.5 0 2 
11-228 583.8 0 3 
11-232 224.2 0 1 
11-244 407.6 0 2 
Average 405.76 0 1.8 
Standard 
Deviation 164.2740789 
 
0.836660027 
Standard Error 73.46560147 0 0.374165739 
 
Non-Ligated 
Right Muscular 
Branch 
   
Block Number 
Cross-Sectional 
Area (μm2) 
Proliferating 
Smooth Muscle 
Cell Count 
Smooth Muscle 
Cell Count 
11-225 4797.7 0 14 
11-229 3113.2 0 8 
11-233 538.8 0 9 
11-237 902.2 0 6 
11-241 2780.3 0 11 
11-245 925.7 0 6 
Average 2176.316667 0 9 
Standard 
Deviation 1672.308165 0 3.098386677 
Standard Error 682.7169494 0 1.264911064 
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Day 7 
Ligated Left 
Gracilis 
   
Block Number 
Cross-Sectional 
Area (μm2) 
Proliferating 
Smooth Muscle 
Cell Count 
Smooth Muscle Cell 
Count 
11-198 a 747.8 3 3 
11-198 b 680.6 3 6 
11-210 a 1207.8 3 3 
11-210 b 980 0 1 
11-218 a 669.5 4 6 
11-218 b 545.7 2 3 
Average 805.2333333 2.5 3.666666667 
Standard 
Deviation 243.8099478 1.378404875 1.966384161 
Standard Error 99.5349944 0.562731434 0.802772972 
 
 
 
 
Ligated Left 
Muscular Branch 
   
Block Number 
Cross-Sectional 
Area (μm2) 
Proliferating 
Smooth Muscle 
Cell Count 
Smooth Muscle Cell 
Count 
11-199 1403.9 0 10 
11-203 475 0 5 
11-207 763.8 0 10 
11-215 4514.6 0 11 
Average 1789.325 0 9 
Standard 
Deviation 1857.850728 
 
2.708012802 
Standard Error 928.9253642 0 1.354006401 
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Non-Ligated 
Right Gracilis 
Block Number 
Cross-Sectional 
Area (μm2) 
Proliferating 
Smooth Muscle 
Cell Count 
Smooth Muscle Cell 
Count 
11-204 a 238.3 0 1 
11-204 b 422.2 0 4 
11-208 687.4 0 3 
11-212 827.7 0 4 
11-220 126.2 0 1 
Average 460.36 0 2.6 
Standard 
Deviation 295.3453792 0 1.516575089 
Standard Error 132.0824689 0 0.678232998 
 
Non-Ligated 
Right Muscular 
Branch 
   
Block Number 
Cross-Sectional 
Area (μm2) 
Proliferating 
Smooth Muscle 
Cell Count 
Smooth Muscle Cell 
Count 
11-205 1407.2 0 5 
11-209 815.7 0 6 
11-213 1786.3 0 8 
11-217 1217 0 6 
11-221 2616 0 10 
Average 1568.44 0 7 
Standard 
Deviation 682.0870274 0 2 
Standard Error 305.038592 0 0.894427191 
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Day 14 
Ligated Left 
Gracilis 
   
Block Number 
Cross-
Sectional 
Area (μm2) 
Proliferating Smooth 
Muscle Cell Count 
Smooth Muscle 
Cell Count 
11-246 2074.7 0 7 
11-254 890.7 0 5 
11-258 2961.5 0 6 
11-262 a 2262.2 0 5 
11-262 b 3461.1 0 5 
11-264a a 2545.9 0 7 
11-264a b 1464.4 0 3 
Average 2237.214286 0 5.428571429 
Standard 
Deviation 871.3161241 0 1.397276262 
Standard Error 329.3265397 0 0.528120786 
 
Ligated Left 
Muscular 
Branch 
   
Block Number 
Cross-
Sectional 
Area (μm2) 
Proliferating Smooth 
Muscle Cell Count 
Smooth Muscle 
Cell Count 
11-195 854.4 0 5 
11-251 1762.6 0 9 
11-255 2144.3 0 8 
11-259 4539 0 8 
11-263b 1751.4 0 7 
11-265 2382.4 0 9 
Average 2239.016667 0 7.666666667 
Standard 
Deviation 1241.076914 0 1.505545305 
Standard Error 506.6675283 0 0.614636297 
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Non-Ligated 
Right Gracilis 
Block Number 
Cross-
Sectional 
Area (μm2) 
Proliferating Smooth 
Muscle Cell Count 
Smooth Muscle 
Cell Count 
11-248 435 0 3 
11-252 273.5 0 2 
11-260 493.2 0 2 
11-264b a 447.1 0 2 
11-264b b 269.1 0 2 
Average 383.58 0 2.2 
Standard 
Deviation 104.7838585 0 0.447213595 
Standard Error 46.86076611 0 0.2 
 
Non-Ligated 
Right Muscular 
Branch 
   
Block Number 
Cross-
Sectional 
Area (μm2) 
Proliferating Smooth 
Muscle Cell Count 
Smooth Muscle 
Cell Count 
11-249 2258.1 0 12 
11-253 1028.4 0 7 
11-257 1339.7 0 8 
11-261 2032 0 7 
Average 1664.55 0 8.5 
Standard 
Deviation 576.638376 0 2.380476143 
Standard Error 288.319188 0 1.190238071 
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Statistical Data 
Average Vessel Cross 
Sectional Area (μm2) 
   
 
Day 3 Day 7 Day 14 
LLG 772.2 805.2 2237.2 
LLMB 1643.8 1789.3 2239 
NLRG 405.8 460.4 383.6 
NLRMB 2176.3 1568.4 1664.6 
    Proliferating Smooth Muscle 
Cells 
   
 
Day 3 Day 7 Day 14 
LLG 1.6 2.5 0 
LLMB N/A N/A N/A 
NLRG N/A N/A N/A 
NLRMB N/A N/A N/A 
    Smooth Muscle Cells 
   
 
Day 3 Day 7 Day 14 
LLG 3.3 3.7 5.4 
LLMB 8.2 9 7.7 
NLRG 1.8 2.6 2.2 
NLRMB 9 7 8.5 
 
ANOVA 
  
p-value 
ischemic Gracilis cross sectional area M1 vs M2   nonsignificant 
 
M1 vs M3   
P<.01 0.000135 
 
M2 vs M3   
P<.01 
 NI gracilis cross sectional area nonsignificant 0.829399 
ischemic MB cross sectional area nonsignificant 0.666342 
NI mb cross sectional area nonsignificant 0.666342 
    ischemic gracilis vsmcs nonsignificant? 0.041199 
NI gracilis vsmcs nonsignificant 0.49327 
ischemic mb vsmcs nonsignificant 0.697779 
ni mb vsmcs nonsignificant 0.455587 
Proliferating vsmcs nonsignificant 0.088831 
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T-Tests 
 NI = Nonischemic,  
I = Ischemic  p-value 
NI vs. I Gracilis Day 3 area 0.052049 
NI vs. I MB Day 3 area 0.241757 
NI vs. I Gracilis Day 3 SMCs 0.012787 
NI vs. I MB Day 3 SMCs 0.319311 
NI vs. I Gracilis D-7 area 0.035269 
NI vs. I MB Day 7 area 0.41617 
NI vs. I Gracilis Day 7 SMCs 0.168312 
NI vs. I MB Day 7 SMCs 0.136281 
NI vs. I Gracilis Day 14 area 0.000708 
NI vs. I MB Day 14 area 0.178619 
NI vs. I Gracilis Day 14 SMCs 0.000223 
NI vs. I MB Day 14 SMCs 0.280574 
MB vs Gracilis cross sectional 
area 
 Day 3 0.002464 
Day 7 0.184761 
Day 14 0.498843 
MB vs gracilis vsmcs 
 Day 3 0.003183 
Day 7 0.00975 
Day 14 0.010033 
Proliferating vsmcs 
 day 3 vs 0 0.000368 
day 7 vs 0 0.003374 
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Vessel Composite Images 
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